Increased prevalence and analysis of risk factors for indinavir nephrolithiasis

Journal of Urology

Volumn 164, Issue 6, 2000, Pages 1895-1897

  Saltel, E ^a,b   Angel, J B ^a   Futter, N G ^a   Walsh, W G ^a   O'Rourke, K ^a   Mahoney, J E ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b American Urological Association   (United States)

Author keywords

Calculi; HIV; Iatrogenic disease; Indinavir; Kidney

Indexed keywords

ALANINE AMINOTRANSFERASE; CREATININE; INDINAVIR;

AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; BODY WEIGHT; CREATININE BLOOD LEVEL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NEPHROLITHIASIS; PREVALENCE; PRIORITY JOURNAL; RELATIVE DENSITY; RISK FACTOR; STONE FORMATION; URINE PH;

EID: 0033763935     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)66911-X     Document Type: Article

References (12)

1. Urinary stones in HIV-1 positive patients treated with indinavir
2. Protease inhibitors show promise in HIV infection
3. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed
4. Les lithiases medicamenteuses
5. Evaluation of urinary pH and specific gravity in the development of indinavir induced renal stones
6. Urine acidification and the risk of nephrolithiasis due to indinavir
7. Management of indinavir associated nephrolithiasis
8. Indinavir-related nephrolithiasis is associated with environmental temperature
9. Urologic complaints in relation to indinavir plasma levels in HIV-infected patients
10. A new type of urinary calculus: Indinavir
11. Protease inhibitors and urolithiasis